Reneo Pharmaceuticals/RPHM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

Ticker

RPHM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Grey

Employees

8

Headquarters

Irvine, United States

RPHM Metrics

BasicAdvanced
$55M
Market cap
-
P/E ratio
-$2.17
EPS
-
Beta
-
Dividend rate
$55M
$9.45
$0.98
261K
29.825
-77.06%
-84.01%
-83.08%
0.683
0.683
1.04%

What the Analysts think about RPHM

Analyst Ratings

Majority rating from 3 analysts.
Hold

RPHM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.4M
-64.26%
Profit margin
0.00%
NaN%

RPHM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 42.75%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.65
-$0.57
-$0.71
-$0.25
-
Expected
-$0.52
-$0.57
-$0.58
-$0.44
-$0.10
Surprise
25.81%
-0.25%
22.88%
-42.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Reneo Pharmaceuticals stock?

Reneo Pharmaceuticals (RPHM) has a market cap of $55M as of June 14, 2024.

What is the P/E ratio for Reneo Pharmaceuticals stock?

The price to earnings (P/E) ratio for Reneo Pharmaceuticals (RPHM) stock is 0 as of June 14, 2024.

Does Reneo Pharmaceuticals stock pay dividends?

No, Reneo Pharmaceuticals (RPHM) stock does not pay dividends to its shareholders as of June 14, 2024.

When is the next Reneo Pharmaceuticals dividend payment date?

Reneo Pharmaceuticals (RPHM) stock does not pay dividends to its shareholders.

What is the beta indicator for Reneo Pharmaceuticals?

Reneo Pharmaceuticals (RPHM) does not currently have a Beta indicator.

What is the Reneo Pharmaceuticals stock price target?

The target price for Reneo Pharmaceuticals (RPHM) stock is $2.25, which is NaN% below the current price of $. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Reneo Pharmaceuticals stock

Buy or sell Reneo Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing